All News
Baricitinib Approved in the EU for Use in Rheumatoid Arthritis
The European Commission has approved Eli Lilly's rheumatoid arthritis drug Olumiant (baricitinib) for use in Europe for RA patients with moderate-to-severe active disease in adults who have not responded one or more disease-modifying antirheumatic drugs.
Read Article
An Integrated Analysis of Tofacitinib Safety
Since its US approval in 2012, tofacitinib has become a widely used treatment for rheumatoid arthritis (RA).
Whether you're impressed with its efficacy, or distressed with its side effects, its track record is voluminous and has been recently reviewed.
Read Article
Novel Peripheral Helper T Cells in RA
US and UK researchers have identified a unique subset of helper T-cells called ‘peripheral helper’ T-cells in the synoviums that may be linked to the pathogenesis of rheumatoid arthritis.
Read Article
No Increase in Infections with Pre-Op Infliximab Before Hip or Knee Replacement
Up to 30% of patients with rheumatoid arthritis (RA) will eventually undergo joint reconstructive surgery, yet we have limited data to guide the perioperative management of DMARDs and biologics.
Read Article
The RheumNow Week in Review – 3 February 2017
Dr. Jack Cush reviews this week's highlights from RheumNow.
Read Article
Kevzara (Sarilumab) Approved in Canada for RA
Kevzara (sarilumab), an interleukin-6 (IL-6) receptor monoclonal antibody, was approved by Health Canada for use in rheumatoid arthritis (RA).
Read Article
Is the Jury Still Out on Triple Therapy vs. MTX + TNF inhibitor?
There are several trials that test the efficacy and safety of combination tumor necrosis factor inhibitor (TNFi) plus methotrexate against triple therapy (methotrexate plus hydroxychloroquine plus sulfasalazine) in patients with rheumatoid arthritis.
Read Article
Curbside Consults - January 2017
Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines.
Read Article
The RheumNow Week in Review – 27 January 2017
Dr. Cush reviews highlights from the past week on RheumNow.com.
Read Article
DSB - Safety Update and Drug Shortages January 2017
RheumNow will periodically report safety issues as Drug Safety Bulletins. These will update you with safety issues, label changes and reports of new, ongoing and resolved drug shortages that affect rheumatology. If you have suggestions or information about specific drug shortages or drug safety issues, please email us at info@rheumnow.com.
Read Article
FDA Issues Draft Guidance on Biosimilar Interchangeability
Interchangeability, or the substitution of a biosimilar for its innovator biologic, is on the horizon. Will the prescriber chose the biosimilar in place of the originator? Or will this allow pharmacists or healthcare plans to substitute a biosimilar, without intervention from a healthcare provider?
Read Article
The RheumNow Week in Review – 20 January 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.
Read Article
Consensus Guidelines for Juvenile Dermatomyositis Management
SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was established in 2012 to optimise the diagnosis and treatment of several pediatric diseases. They have recently published their recommendations regarding the diagnosis and management of juvenile dermatomyositis (JDM).
Read Article
Rituximab Effects on ANCA, IgG and Infectious Risk in ANCA-Associated Vasculitis
Rituximab has significantly changed the management of patiehts with ANCA-associated vasculitis (AAV). Yet the longitudinal assessment of such patients needs to be guideded by clinical and laboratory parameters.
Read Article
The RheumNow Week in Review – 13 January 2017
Dr. Jack Cush reviews highlights from this past week on RheumNow.com:
Read Article
TREG Innovators Win the Crafoord Prize
The 2017 Crafoord Prize from the Royal Swedish Academy of Sciences has been awarded to a Japanese scientists and two American scientists for their discovery and research on T regulatory cells (TRegs).
Read Article
Less Education Yields Higher Cardiovascular Risk
Similar to the findings in rheumatoid arthritis, lower levels of education can have predictable negative consequences. And the reasons for more heart attacks with lower educational levels is not entirely clear.
Read Article
The RheumNow Week in Review – 6 January 2017
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Read Article
Pregnancy Outcomes in Psoriatic Arthritis
Disease Activity Pre-pregnancy During Pregnancy Post-pregnancy
Mild 10 6 4
Moderate 2 6 8
Severe 2 2 2
DMARDs Under Study for Secondary Prevention of Cardiovascular Events
Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.
Read Article